Thomas Diraimondo
Chief Scientific OfficerDr. Tommy Diraimondo, Ph.D. serves as Chief Scientific Officer Since January 2024 and served as Executive Director, Research & Development for Janux Therapeutics, Inc. and Head of Research and Development from January 2023 through December 2023. He served as Director of Research at Janux Therapeutics, Inc. until 2022 and was its Senior Director of Research from 2022. He joined the Janux Therapeutics team in May 2018 and served as the Director of Research. He manages the internal and external research operations and has been an integral part in the creation and reduction to practice of key technologies protected by the ever-growing Janux intellectual property portfolio. Before Janux, he was the co-founder of Sitari Pharmaceuticals based upon his graduate work at Stanford University with Professor Chaitan Khosla. He was a key leader in the Sitari drug discovery and development program, whose successful culmination was the acquisition by GlaxoSmithKline. He earned his Ph.D. in Chemical Engineering from Stanford University, his M.S.E. in Pharmaceutical Engineering and his B.S.E in Chemical Engineering from the University of Michigan, Ann Arbor.
Positions
- Company NameJanux Therapeutics, Inc.Stock CodeJANXPositionChief Scientific OfficerColleagues
- DADavid Alan CampbellPresident, Co-Founder, CEO & Director
- RWRonald W. BarrettIndependent Chairperson
- JDJaneen DoyleChief Corporate & Business Development Officer
- MWMatt WhitmireVice President of Finance
- MDMaria DobekVice President of Accounting
- JSJake SimsonIndependent Director
- VLVickie L. CappsIndependent Director
- WKWinston KungIndependent Director
